Single Biggest Cancer Dictionary in the World

What is autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes?

Pronunciation: /autologous* ˈænˌti egfr* kɑr transduced* cxcr* faɪv ˈmɑdəˌfaɪd ti ˈlɪmfəˌsaɪts/

autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes

Definition

A preparation of autologous, C-X-C chemokine receptor type 5 (CXCR 5)-modified T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-EGFR CAR-transduced CXCR 5-modified T lymphocytes target and bind to EGFR-expressing tumor cells, thereby inducing selective toxicity in EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. CXCR5, and its ligand C-X-C motif chemokine 13 (CXCL13), are associated with a variety of tumors. CXCR5-CXCL13 interactions may be involved in the regulation of lymphocyte infiltration within the tumor microenvironment (TME).